iBio director William D. Clark granted 38,000 options

Monthly vesting spans twelve months and depends on continued service through each applicable vesting date.

Rhea-AI Filing Summary

iBio, Inc. director William D. Clark acquired a direct option award covering 38,000 shares on October 14, 2026, with an exercise price of $0.78 per share and an expiration date of October 13, 2036. The options vest pro rata in monthly installments over twelve months, beginning one month after the grant date, subject to his continued service through each applicable vesting date.

Insider Trade Summary

Grant/Award: 38,000 shares

Grant/Award 1 txn

Insider Clark William D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	38,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,000 contracts (Direct)

Footnotes (1)

1. F1. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

Key Figures

Option award: 38,000 options Exercise price: $0.78 per share Vesting period: 12 months +1 more

4 metrics

Option award 38,000 options Granted October 14, 2026

Exercise price $0.78 per share Price to acquire the underlying common stock

Vesting period 12 months Monthly installments, beginning one month after the grant date

Expiration date October 13, 2036 Option award

Key Terms

pro rata, exercise price, expiration date

3 terms

pro rata financial

"the options vest pro rata in monthly installments"

Pro rata means dividing or distributing something proportionally based on a specific factor, such as ownership or contribution. For example, if an investor owns 10% of a company, they would receive 10% of any dividends or benefits allocated. This approach ensures everyone gets their fair share relative to their stake or input, helping investors understand how benefits, costs, or responsibilities are fairly shared.

exercise price financial

"the options' exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"the option's expiration date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did IBIO director William D. Clark receive?

William D. Clark received options covering 38,000 shares at an exercise price of $0.78 per share on October 14, 2026. The options vest monthly over twelve months, subject to continued service through each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 06:32 PM EDT Accepted by SEC EDGAR 10/15/2026 - 06:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark William D

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$0.78	10/14/2026		A		38,000(1)		(1)	10/13/2036	Common Stock	38,000	$0	38,000	D

Explanation of Responses:

1. The options vest pro rata in monthly installments over twelve months, with the first installment vesting one month after the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Marc Banjak, Attorney-in-fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)